That BAX and MNTA are now working on the third FoB in the collaboration presumably means that BAX has exercised the option to develop compounds #3-#6, which results in a $28M milestone payment to MNTA—see #msg-70258421.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”